Aratana nears approval for canine cancer vaccine

Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018. The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news

Related Links:

Publication date: Available online 1 June 2020Source: MethodsAuthor(s): Reyhaneh Manafi-Farid, Najme Karamzade-Ziarati, Reza Vali, Felix M. Mottaghy, Mohsen Beheshti
Source: Methods - Category: Molecular Biology Source Type: research
Publication date: Available online 2 June 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Cell ResearchAuthor(s): Dipanwita Das Mukherjee, N. Maruthi Kumar, Mukund P. Tantak, Satabdi Datta, Debabrata Ghosh Dastidar, Dalip Kumar, Gopal Chakrabarti
Source: Biochimica et Biophysica Acta (BBA) Molecular Cell Research - Category: Molecular Biology Source Type: research
Authors: Barber MRW, Clarke AE Abstract INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects almost every organ system and it is treated with immunomodulation and immunosuppression. SLE patients have an intrinsically dysfunctional immune system which is exacerbated by disease activity and leaves them vulnerable to infection. Treatment with immunosuppression increases susceptibility to infection, while hydroxychloroquine use decreases this risk. Infectious diseases are a leading cause of hospitalization and death. AREAS COVERED: This narrative review provides an overview of rec...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
Th17 cells (producing IL-17) and Th9 cells (producing IL-9) exhibit functional plasticity, and their role in tumorigenicity is controversial. Th17/IL-17 and Th9/IL-9 exhibit critical, but often opposing, roles in tumor progression. In this issue of the JCI, Salazar et al. show that while IL-17 and IL-9 induced distinct but complementary molecular pathways, both cytokines also induced epithelial-mesenchymal transition (EMT) in lung cancer cells and promoted metastatic spreading. A key question before us now is whether IL-9 and IL-17 contribute to tumor progression in a sequential and stage-specific manner within the tumor microenvironment.
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Emerging immune therapy, such as with the anti–programmed cell death–1 (anti–PD-1) monoclonal antibody nivolumab, has shown efficacy in tumor suppression. Patients with terminal cancer suffer from cancer pain as a result of bone metastasis and bone destruction, but how PD-1 blockade affects bone cancer pain remains unknown. Here, we report that mice lacking Pdcd1 (Pd1−/−) demonstrated remarkable protection against bone destruction induced by femoral inoculation of Lewis lung cancer cells. Compared with WT mice, Pd1−/− mice exhibited increased baseline pain sensitivity, but the deve...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
(Morris Animal Foundation) Morris Animal Foundation has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with the deadly bone tumor, osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment which combines a molecule expressed by cancer cells with a modified live form of the bacteria Listeria monocytogenes.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Aratana Therapeutics Inc.'s cancer immunotherapy drug for dogs gained a conditional license from the U.S. Department of Agriculture, the company announced Wednesday. To gain full licensure, Aratana (Nasdaq; PETX) will start another field study in early 2018. The vaccine initially will be available for purchase at 12 veterinary oncology practices participating in the study. It's designed to treat dogs with bone cancer after the tumor is surgically removed. It works using listeria, a type of bacteria,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
CONCLUSIONS: These findings demonstrate that ADXS31-164 administered in the setting of minimal residual disease, can induce HER2/neu specific immunity and may reduce the incidence of metastatic disease and prolong overall survival in a clinically relevant, spontaneous, large animal model of cancer. These findings therefore, have important translational relevance for children with osteosarcoma and adults with other HER2/neu+ cancers. PMID: 26994144 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
The purpose of this study is to determine the safety and efficacy of a highly attenuated recombinant Listeria monocytogenes expressing a chimeric human HER2/neu (Lm-LLO-HER2/neu) in combination with palliative radiation (RT) to induce HER2 specific immunity and delay tumor progression in dogs with spontaneous osteosarcoma (OSA). Dogs develop OSA that recapitulates many aspects of human OSA, and are recognized as a clinically relevant, large animal model in which to evaluate novel therapies. Previously we have shown that Lm-LLO-HER2/neu administration to dogs with HER2+ OSA following amputation and chemotherapy is safe, bre...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Clinical Research (Excluding Clinical Trials) Source Type: research
More News: Bone Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Health Management | Immunotherapy | Listeria | Study | Vaccines | Veterinary Research | Veterinary Vaccinations